George L Drusano,
DIR & PROF
Department:
MD-INST FOR THERAPEUTIC INNOV
Business Phone:
(407) 313-7060
Business Email:
gdrusano@ufl.edu
Accomplishments
Recipient University of Florida Research Foundation Professorship
2018
·
University of Florida
Paul Ehrlich Magic Bullet Award
2015
·
Paracelsus University, Nurnberg, Germany
ICAAC Award
2013
·
American Society for Microbiology
Recipient, Maxwell Finland Award; Dr. Anthony Fauci a prior recipient
2012
·
National Foundation for Infectious Diseases
Editor, Mbio
2010-2015
·
American Society for Microbiology
Communicating Chair, Gordon Research Conference: New antibacterial drug discovery and development
2010
·
Gordon Research Conference
Fellow, American Academy of Microbiology
2009
·
American Society of Microbiology
Distinguished Investigator
2003
·
American College of Clinical Pharmacology
Editor, Antimicrobial Agents and Chemotherapy
1989-1997
·
American Society for Microbiology
Teaching Profile
Courses Taught
2021,2023-2024
PHA6133 Translational Clinical Pharmacology
Publications
2024
Pharmacodynamic evaluation of ceftriaxone single-dose therapy (0.125-1 g) to eradicate ceftriaxone-susceptible and ceftriaxone-resistant Neisseria gonorrhoeae strains in a hollow fibre infection model for gonorrhoea.
The Journal of antimicrobial chemotherapy.
[DOI] 10.1093/jac/dkae063.
[PMID] 38497988.
2024
Population pharmacokinetics and humanized dosage regimens matching the peak, area, trough, and range of amikacin plasma concentrations in immune-competent murine bloodstream and lung infection models.
Antimicrobial agents and chemotherapy.
68(3)
[DOI] 10.1128/aac.01394-23.
[PMID] 38289076.
2023
A five-day treatment course of zanamivir for the flu with a single, self-administered, painless microneedle array patch: Revolutionizing delivery of poorly membrane-permeable therapeutics.
International journal of pharmaceutics.
641
[DOI] 10.1016/j.ijpharm.2023.123081.
[PMID] 37230371.
2023
Combination Therapy with UV-4B and Molnupiravir Enhances SARS-CoV-2 Suppression.
Viruses.
15(5)
[DOI] 10.3390/v15051175.
[PMID] 37243261.
2023
Correction: 2-Mercaptomethyl-thiazolidines use conserved aromatic-S interactions to achieve broad-range inhibition of metallo-β-lactamases.
Chemical science.
14(34)
[DOI] 10.1039/d3sc90150e.
[PMID] 37655038.
2023
Individual Components of Polymyxin B Modeled via Population Pharmacokinetics to Design Humanized Dosage Regimens for a Bloodstream and Lung Infection Model in Immune-Competent Mice.
Antimicrobial agents and chemotherapy.
67(5)
[DOI] 10.1128/aac.00197-23.
[PMID] 37022153.
2023
Pharmacodynamics of zoliflodacin plus doxycycline combination therapy against Neisseria gonorrhoeae in a gonococcal hollow-fiber infection model.
Frontiers in pharmacology.
14
[DOI] 10.3389/fphar.2023.1291885.
[PMID] 38130409.
2022
Combination Therapy to Kill Mycobacterium tuberculosis in Its Nonreplicating Persister Phenotype.
Antimicrobial agents and chemotherapy.
66(10)
[DOI] 10.1128/aac.00695-22.
[PMID] 36165631.
2022
Evaluating the effect of clofazimine against Mycobacterium tuberculosis given alone or in combination with pretomanid, bedaquiline or linezolid.
International journal of antimicrobial agents.
59(2)
[DOI] 10.1016/j.ijantimicag.2021.106509.
[PMID] 34958863.
2022
Individualized Patient Care Through Model-Informed Precision Dosing: Reflections on Training Future Practitioners.
The AAPS journal.
24(6)
[DOI] 10.1208/s12248-022-00769-z.
[PMID] 36380020.
2022
Pharmacodynamic evaluation of lefamulin in the treatment of gonorrhea using a hollow fiber infection model simulating Neisseria gonorrhoeae infections.
Frontiers in pharmacology.
13
[DOI] 10.3389/fphar.2022.1035841.
[PMID] 36452226.
2022
Pharmacodynamic Evaluation of Zoliflodacin Treatment of Neisseria gonorrhoeae Strains With Amino Acid Substitutions in the Zoliflodacin Target GyrB Using a Dynamic Hollow Fiber Infection Model.
Frontiers in pharmacology.
13
[DOI] 10.3389/fphar.2022.874176.
[PMID] 35496288.
2022
Why Molnupiravir Fails in Hospitalized Patients.
mBio.
13(6)
[DOI] 10.1128/mbio.02916-22.
[PMID] 36374076.
2021
“One-Two Punch”: Synergistic ß-Lactam Combinations for Mycobacterium abscessus and Target Redundancy in the Inhibition of Peptidoglycan Synthesis Enzymes.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
73(8):1532-1536
[DOI] 10.1093/cid/ciab535.
[PMID] 34113990.
2021
2-Mercaptomethyl Thiazolidines (MMTZs) Inhibit All Metallo-β-Lactamase Classes by Maintaining a Conserved Binding Mode.
ACS infectious diseases.
7(9):2697-2706
[DOI] 10.1021/acsinfecdis.1c00194.
[PMID] 34355567.
2021
2-Mercaptomethyl-thiazolidines use conserved aromatic-S interactions to achieve broad-range inhibition of metallo-β-lactamases.
Chemical science.
12(8):2898-2908
[DOI] 10.1039/d0sc05172a.
[PMID] 34164056.
2021
Building Optimal Three-Drug Combination Chemotherapy Regimens To Eradicate Mycobacterium tuberculosis in Its Slow-Growth Acid Phase.
Antimicrobial agents and chemotherapy.
65(10)
[DOI] 10.1128/AAC.00693-21.
[PMID] 34339275.
2021
Combating Multidrug-Resistant Bacteria by Integrating a Novel Target Site Penetration and Receptor Binding Assay Platform Into Translational Modeling.
Clinical pharmacology and therapeutics.
109(4):1000-1020
[DOI] 10.1002/cpt.2205.
[PMID] 33576025.
2021
Dose Fractionation of Moxifloxacin for Treatment of Tuberculosis: Impact of Dosing Interval and Elimination Half-Life on Microbial Kill and Resistance Suppression.
Antimicrobial agents and chemotherapy.
65(4)
[DOI] 10.1128/AAC.02533-20.
[PMID] 33468465.
2021
Emergence of Resistance to Ceftazidime-Avibactam in a Pseudomonas aeruginosa Isolate Producing Derepressed blaPDC in a Hollow-Fiber Infection Model.
Antimicrobial agents and chemotherapy.
65(6)
[DOI] 10.1128/AAC.00124-21.
[PMID] 33782013.
2021
Pharmacodynamic Evaluation of Dosing, Bacterial Kill, and Resistance Suppression for Zoliflodacin Against Neisseria gonorrhoeae in a Dynamic Hollow Fiber Infection Model.
Frontiers in pharmacology.
12
[DOI] 10.3389/fphar.2021.682135.
[PMID] 34093206.
2021
Polymyxin B Pharmacodynamics in the Hollow-Fiber Infection Model: What You See May Not Be What You Get.
Antimicrobial agents and chemotherapy.
65(8)
[DOI] 10.1128/AAC.01853-20.
[PMID] 34097487.
2021
The case for precision dosing: medical conservatism does not justify inaction.
The Journal of antimicrobial chemotherapy.
76(7):1661-1665
[DOI] 10.1093/jac/dkab086.
[PMID] 33843994.
2021
The Funnel: a Screening Technique for Identifying Optimal Two-Drug Combination Chemotherapy Regimens.
Antimicrobial agents and chemotherapy.
65(2)
[DOI] 10.1128/AAC.02172-20.
[PMID] 33199386.
2021
Vancomycin Area Under the Curve-Guided Dosing and Monitoring for Adult and Pediatric Patients With Suspected or Documented Serious Methicillin-Resistant Staphylococcus aureus Infections: Putting the Safety of Our Patients First.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
72(9):1497-1501
[DOI] 10.1093/cid/ciaa1744.
[PMID] 33740042.
2020
Building Optimal Three-Drug Combination Chemotherapy Regimens.
Antimicrobial agents and chemotherapy.
64(11)
[DOI] 10.1128/AAC.01610-20.
[PMID] 32900682.
2020
Developing New Drugs for Mycobacterium tuberculosis Therapy: What Information Do We Get from Preclinical Animal Models?
Antimicrobial agents and chemotherapy.
64(12)
[DOI] 10.1128/AAC.01376-20.
[PMID] 32958720.
2020
Development of New Antimicrobials for Urogenital Gonorrhea Therapy: Clinical Trial Design Considerations.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
70(7):1495-1500
[DOI] 10.1093/cid/ciz899.
[PMID] 31538646.
2020
First Penicillin-Binding Protein Occupancy Patterns for 15 β-Lactams and β-Lactamase Inhibitors in Mycobacterium abscessus.
Antimicrobial agents and chemotherapy.
65(1)
[DOI] 10.1128/AAC.01956-20.
[PMID] 33106266.
2020
Methodological features of clinical pharmacokinetic-pharmacodynamic studies of antibacterials and antifungals: a systematic review.
The Journal of antimicrobial chemotherapy.
75(6):1374-1389
[DOI] 10.1093/jac/dkaa005.
[PMID] 32083674.
2020
Novel Cassette Assay To Quantify the Outer Membrane Permeability of Five β-Lactams Simultaneously in Carbapenem-Resistant Klebsiella pneumoniae and Enterobacter cloacae.
mBio.
11(1)
[DOI] 10.1128/mBio.03189-19.
[PMID] 32047131.
2020
Optimising treatments for sexually transmitted infections: surveillance, pharmacokinetics and pharmacodynamics, therapeutic strategies, and molecular resistance prediction.
The Lancet. Infectious diseases.
20(8):e181-e191
[DOI] 10.1016/S1473-3099(20)30171-7.
[PMID] 32569625.
2020
Pharmacodynamics of Cefepime Combined with the Novel Extended-Spectrum-β-Lactamase (ESBL) Inhibitor Enmetazobactam for Murine Pneumonia Caused by ESBL-Producing Klebsiella pneumoniae.
Antimicrobial agents and chemotherapy.
64(6)
[DOI] 10.1128/AAC.00180-20.
[PMID] 32253209.
2020
Pharmacokinetic/pharmacodynamic considerations for new and current therapeutic drugs for uncomplicated gonorrhoea-challenges and opportunities.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
26(12):1630-1635
[DOI] 10.1016/j.cmi.2020.08.006.
[PMID] 32798687.
2020
Pharmacokinetics of tedizolid, sutezolid, and sutezolid-M1 in non-human primates.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
151
[DOI] 10.1016/j.ejps.2020.105421.
[PMID] 32531349.
2020
Polymyxin Susceptibility Testing and Interpretive Breakpoints: Recommendations from the United States Committee on Antimicrobial Susceptibility Testing (USCAST).
Antimicrobial agents and chemotherapy.
64(2)
[DOI] 10.1128/AAC.01495-19.
[PMID] 31767718.
2019
Breakpoint determination when multiple organisms are tested for effect targets.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
130:196-199
[DOI] 10.1016/j.ejps.2019.01.033.
[PMID] 30711687.
2019
Ceftazidime-Avibactam in Combination With Fosfomycin: A Novel Therapeutic Strategy Against Multidrug-Resistant Pseudomonas aeruginosa.
The Journal of infectious diseases.
220(4):666-676
[DOI] 10.1093/infdis/jiz149.
[PMID] 31099835.
2019
Cerebrospinal pharmacokinetic and pharmacodynamic analysis of efficacy of meropenem in paediatric patients with bacterial meningitis.
International journal of antimicrobial agents.
54(3):292-300
[DOI] 10.1016/j.ijantimicag.2019.06.021.
[PMID] 31279154.
2019
Comparable Efficacy and Better Safety of Double β-Lactam Combination Therapy versus β‑Lactam plus Aminoglycoside in Gram-Negative Bacteria in Randomized, Controlled Trials.
Antimicrobial agents and chemotherapy.
63(7)
[DOI] 10.1128/AAC.00425-19.
[PMID] 30988147.
2019
Considerations for Dose Selection and Clinical Pharmacokinetics/Pharmacodynamics for the Development of Antibacterial Agents.
Antimicrobial agents and chemotherapy.
63(5)
[DOI] 10.1128/AAC.02309-18.
[PMID] 30833427.
2019
Dose optimization of moxifloxacin and linezolid against tuberculosis using mathematical modeling and simulation.
International journal of antimicrobial agents.
53(3):275-283
[DOI] 10.1016/j.ijantimicag.2018.10.012.
[PMID] 30385322.
2019
Effect of Moxifloxacin plus Pretomanid against Mycobacterium tuberculosis in Log Phase, Acid Phase, and Nonreplicating-Persister Phase in an In Vitro Assay.
Antimicrobial agents and chemotherapy.
63(1)
[DOI] 10.1128/AAC.01695-18.
[PMID] 30397058.
2019
Four Decades of β-Lactam Antibiotic Pharmacokinetics in Cystic Fibrosis.
Clinical pharmacokinetics.
58(2):143-156
[DOI] 10.1007/s40262-018-0678-x.
[PMID] 29936678.
2019
GC-072: A Novel Therapeutic Candidate for Oral Treatment of Melioidosis and Infections Caused by Select Biothreat Pathogens.
Antimicrobial agents and chemotherapy.
63(12)
[DOI] 10.1128/AAC.00834-19.
[PMID] 31548183.
2019
Generating Robust and Informative Nonclinical In Vitro and In Vivo Bacterial Infection Model Efficacy Data To Support Translation to Humans.
Antimicrobial agents and chemotherapy.
63(5)
[DOI] 10.1128/AAC.02307-18.
[PMID] 30833428.
2019
In vitro antimicrobial combination testing of and evolution of resistance to the first-in-class spiropyrimidinetrione zoliflodacin combined with six therapeutically relevant antimicrobials for Neisseria gonorrhoeae.
The Journal of antimicrobial chemotherapy.
74(12):3521-3529
[DOI] 10.1093/jac/dkz376.
[PMID] 31730160.
2019
Is Daptomycin plus Ceftaroline the Way To Go for Methicillin-Resistant Staphylococcus aureus Bacteremia?
Antimicrobial agents and chemotherapy.
63(11)
[DOI] 10.1128/AAC.01725-19.
[PMID] 31640979.
2019
Natural history of Acinetobacter baumannii infection in mice.
PloS one.
14(7)
[DOI] 10.1371/journal.pone.0219824.
[PMID] 31318907.
2019
Pharmacodynamics of Ceftazidime plus Avibactam against KPC-2-Bearing Isolates of Klebsiella pneumoniae in a Hollow Fiber Infection Model.
Antimicrobial agents and chemotherapy.
63(8)
[DOI] 10.1128/AAC.00462-19.
[PMID] 31160285.
2018
Activity of Moxifloxacin against Mycobacterium tuberculosis in Acid Phase and Nonreplicative-Persister Phenotype Phase in a Hollow-Fiber Infection Model.
Antimicrobial agents and chemotherapy.
62(12)
[DOI] 10.1128/AAC.01470-18.
[PMID] 30249693.
2018
Antiviral Effects of Clinically-Relevant Interferon-α and Ribavirin Regimens against Dengue Virus in the Hollow Fiber Infection Model (HFIM).
Viruses.
10(6)
[DOI] 10.3390/v10060317.
[PMID] 29890736.
2018
Determination of the Dynamically Linked Indices of Fosfomycin for Pseudomonas aeruginosa in the Hollow Fiber Infection Model.
Antimicrobial agents and chemotherapy.
62(6)
[DOI] 10.1128/AAC.02627-17.
[PMID] 29581114.
2018
Dilution Factor of Quantitative Bacterial Cultures Obtained by Bronchoalveolar Lavage in Patients with Ventilator-Associated Bacterial Pneumonia.
Antimicrobial agents and chemotherapy.
62(1)
[DOI] 10.1128/AAC.01323-17.
[PMID] 29038277.
2018
Effect of Linezolid Plus Bedaquiline Against Mycobacterium Tuberculosis in Log Phase, Acid Phase, and Nonreplicating-Persister Phase in An in Vitro Assay
Antimicrobial Agents and Chemotherapy.
62(8)
[DOI] 10.1128/AAC.00856-18;e00856-18.
2018
Effect of Linezolid plus Bedaquiline against Mycobacterium tuberculosis in Log Phase, Acid Phase, and Nonreplicating-Persister Phase in an In Vitro Assay.
Antimicrobial agents and chemotherapy.
62(8)
[DOI] 10.1128/AAC.00856-18.
[PMID] 29866874.
2018
Erratum for Drusano et al., “Dilution Factor of Quantitative Bacterial Cultures Obtained by Bronchoalveolar Lavage in Patients with Ventilator-Associated Bacterial Pneumonia”.
Antimicrobial agents and chemotherapy.
62(4)
[DOI] 10.1128/AAC.00198-18.
[PMID] 29588353.
2018
First Penicillin-Binding Protein Occupancy Patterns of β-Lactams and β-Lactamase Inhibitors in Klebsiella pneumoniae.
Antimicrobial agents and chemotherapy.
62(6)
[DOI] 10.1128/AAC.00282-18.
[PMID] 29712652.
2018
Linezolid Kills Acid-Phase and Nonreplicative-Persister-Phase Mycobacterium tuberculosis in a Hollow-Fiber Infection Model.
Antimicrobial agents and chemotherapy.
62(8)
[DOI] 10.1128/AAC.00221-18.
[PMID] 29866864.
2018
Oseltamivir-zanamivir combination therapy suppresses drug-resistant H1N1 influenza A viruses in the hollow fiber infection model (HFIM) system.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
111:443-449
[DOI] 10.1016/j.ejps.2017.10.027.
[PMID] 29079337.
2018
The Combination of Fosfomycin plus Meropenem Is Synergistic for Pseudomonas aeruginosa PAO1 in a Hollow-Fiber Infection Model.
Antimicrobial agents and chemotherapy.
62(12)
[DOI] 10.1128/AAC.01682-18.
[PMID] 30249700.
2017
Evaluation of Combination Drug Therapy for Treatment of Antibiotic-Resistant Inhalation Anthrax in a Murine Model.
Antimicrobial agents and chemotherapy.
61(9)
[DOI] 10.1128/AAC.00788-17.
[PMID] 28696235.
2017
Pre-clinical in vitro infection models.
Current opinion in pharmacology.
36:100-106
[DOI] 10.1016/j.coph.2017.09.011.
[PMID] 29035729.
2017
Reply to Scagnolari et al.
The Journal of infectious diseases.
215(3):493-494
[DOI] 10.1093/infdis/jiw580.
[PMID] 28003357.
2017
Searching for synergy: Identifying optimal antiviral combination therapy using Hepatitis C virus (HCV) agents in a replicon system.
Antiviral research.
146:149-152
[DOI] 10.1016/j.antiviral.2017.09.001.
[PMID] 28882564.
2017
Sofosbuvir (SOF) Suppresses Ledipasvir (LDV)-resistant Mutants during SOF/LDV Combination Therapy against Genotype 1b Hepatitis C Virus (HCV).
Scientific reports.
7(1)
[DOI] 10.1038/s41598-017-15007-2.
[PMID] 29089577.
2017
Stepping Off the Resistance Treadmill.
The Journal of infectious diseases.
216(2):150-152
[DOI] 10.1093/infdis/jix212.
[PMID] 28475769.
2016
Chikungunya Virus: In Vitro Response to Combination Therapy With Ribavirin and Interferon Alfa 2a.
The Journal of infectious diseases.
214(8):1192-7
[DOI] 10.1093/infdis/jiw358.
[PMID] 27496974.
2016
From lead optimization to NDA approval for a new antimicrobial: Use of pre-clinical effect models and pharmacokinetic/pharmacodynamic mathematical modeling.
Bioorganic & medicinal chemistry.
24(24):6401-6408
[DOI] 10.1016/j.bmc.2016.08.034.
[PMID] 27612961.
2016
Natural History of Francisella tularensis in Aerosol-Challenged BALB/c Mice.
Antimicrobial agents and chemotherapy.
60(3):1834-40
[DOI] 10.1128/AAC.02887-15.
[PMID] 26824958.
2016
Pharmacodynamics for antifungal drug development: an approach for acceleration, risk minimization and demonstration of causality.
The Journal of antimicrobial chemotherapy.
71(11):3008-3019
[PMID] 27494925.
2015
Combination treatment with meropenem plus levofloxacin is synergistic against Pseudomonas aeruginosa infection in a murine model of pneumonia.
The Journal of infectious diseases.
211(8):1326-33
[DOI] 10.1093/infdis/jiu603.
[PMID] 25362196.
2015
Evaluation of Daptomycin Exposure and Efficacy and Safety Endpoints To Support Risk-versus-Benefit Considerations.
Antimicrobial agents and chemotherapy.
60(3):1600-7
[DOI] 10.1128/AAC.02967-15.
[PMID] 26711755.
2015
In memoriam: William A. Craig.
Antimicrobial agents and chemotherapy.
59(6)
[DOI] 10.1128/AAC.00849-15.
[PMID] 25896702.
2015
Pharmacodynamic evaluation of the activities of six parenteral vancomycin products available in the United States.
Antimicrobial agents and chemotherapy.
59(1):622-32
[DOI] 10.1128/AAC.03710-14.
[PMID] 25385113.
2015
Pharmacodynamics of fosfomycin: insights into clinical use for antimicrobial resistance.
Antimicrobial agents and chemotherapy.
59(9):5602-10
[DOI] 10.1128/AAC.00752-15.
[PMID] 26124169.
2015
Pharmacokinetic determinants of virological response to raltegravir in the in vitro pharmacodynamic hollow-fiber infection model system.
Antimicrobial agents and chemotherapy.
59(7):3771-7
[DOI] 10.1128/AAC.00469-15.
[PMID] 25870053.
2015
Pharmacokinetic-pharmacodynamic analysis for efficacy of ceftaroline fosamil in patients with acute bacterial skin and skin structure infections.
Antimicrobial agents and chemotherapy.
59(1):372-80
[DOI] 10.1128/AAC.02531-14.
[PMID] 25367904.
2015
Preclinical Evaluations To Identify Optimal Linezolid Regimens for Tuberculosis Therapy.
mBio.
6(6):e01741-15
[DOI] 10.1128/mBio.01741-15.
[PMID] 26530386.
2015
Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 1.
Antimicrobial agents and chemotherapy.
60(3):1183-93
[DOI] 10.1128/AAC.02177-15.
[PMID] 26711759.
2015
Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 2.
Antimicrobial agents and chemotherapy.
60(3):1194-201
[DOI] 10.1128/AAC.02231-15.
[PMID] 26711766.
2014
Activities of ceftazidime and avibactam against β-lactamase-producing Enterobacteriaceae in a hollow-fiber pharmacodynamic model.
Antimicrobial agents and chemotherapy.
58(6):3366-72
[DOI] 10.1128/AAC.00080-14.
[PMID] 24687507.
2014
Analysis of combination drug therapy to develop regimens with shortened duration of treatment for tuberculosis.
PloS one.
9(7)
[DOI] 10.1371/journal.pone.0101311.
[PMID] 25003557.
2014
Are vancomycin trough concentrations adequate for optimal dosing?
Antimicrobial agents and chemotherapy.
58(1):309-16
[DOI] 10.1128/AAC.01653-13.
[PMID] 24165176.
2014
Evaluation of imipenem for prophylaxis and therapy of Yersinia pestis delivered by aerosol in a mouse model of pneumonic plague.
Antimicrobial agents and chemotherapy.
58(6):3276-84
[DOI] 10.1128/AAC.02420-14.
[PMID] 24687492.
2014
In memoriam: John P. Quinn, MD.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
58(5):748-50
[DOI] 10.1093/cid/cit801.
[PMID] 24336826.
2014
Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions.
The Lancet. Infectious diseases.
14(6):498-509
[DOI] 10.1016/S1473-3099(14)70036-2.
[PMID] 24768475.
2014
Interaction of drug- and granulocyte-mediated killing of Pseudomonas aeruginosa in a murine pneumonia model.
The Journal of infectious diseases.
210(8):1319-24
[DOI] 10.1093/infdis/jiu237.
[PMID] 24760199.
2014
Quantifying the matrix of relationships between reduced vancomycin susceptibility phenotypes and outcomes among patients with MRSA bloodstream infections treated with vancomycin .
The Journal of antimicrobial chemotherapy.
69(9):2547-55
[DOI] 10.1093/jac/dku135.
[PMID] 24840624.
2014
Use of pharmacokinetic/pharmacodynamic systems analyses to inform dose selection of tedizolid phosphate.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
58 Suppl 1:S28-34
[DOI] 10.1093/cid/cit615.
[PMID] 24343829.
2014
Vancomycin exposure in patients with methicillin-resistant Staphylococcus aureus bloodstream infections: how much is enough?
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
59(5):666-75
[DOI] 10.1093/cid/ciu398.
[PMID] 24867791.
2013
Hollow-fiber pharmacodynamic studies and mathematical modeling to predict the efficacy of amoxicillin for anthrax postexposure prophylaxis in pregnant women and children.
Antimicrobial agents and chemotherapy.
57(12):5946-60
[DOI] 10.1128/AAC.02616-12.
[PMID] 24041894.
2013
Impact of meropenem in combination with tobramycin in a murine model of Pseudomonas aeruginosa pneumonia.
Antimicrobial agents and chemotherapy.
57(6):2788-92
[DOI] 10.1128/AAC.02624-12.
[PMID] 23571540.
2013
Natural history of Yersinia pestis pneumonia in aerosol-challenged BALB/c mice.
Antimicrobial agents and chemotherapy.
57(5):2010-5
[DOI] 10.1128/AAC.02504-12.
[PMID] 23403418.
2013
Saving lives with optimal antimicrobial chemotherapy.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
56(2):245-7
[DOI] 10.1093/cid/cis863.
[PMID] 23074312.
2012
Antibiotic Choices and Resistance Suppression for Pseudomonas Aeruginosa
Journal of Veterinary Pharmacology and Therapeutics.
35:2-182
[DOI] 10.1111/jvp.12004.
[PMID] 23082868.
2012
Differential effects of linezolid and ciprofloxacin on toxin production by Bacillus anthracis in an in vitro pharmacodynamic system.
Antimicrobial agents and chemotherapy.
56(1):513-7
[DOI] 10.1128/AAC.05724-11.
[PMID] 22064542.
2012
Dosing regimen matters: the importance of early intervention and rapid attainment of the pharmacokinetic/pharmacodynamic target.
Antimicrobial agents and chemotherapy.
56(6):2795-805
[DOI] 10.1128/AAC.05360-11.
[PMID] 22371890.
2012
Early endpoints for acute bacterial skin and skin structure infections.
Antimicrobial agents and chemotherapy.
56(5):2221-2
[DOI] 10.1128/AAC.00157-12.
[PMID] 22314521.
2012
Effect of coadministration of moxifloxacin and rifampin on Mycobacterium tuberculosis in a murine aerosol infection model.
Antimicrobial agents and chemotherapy.
56(6):3054-7
[DOI] 10.1128/AAC.06383-11.
[PMID] 22470118.
2012
Ertapenem pharmacokinetics and pharmacodynamics during continuous ambulatory peritoneal dialysis.
Antimicrobial agents and chemotherapy.
56(2):725-30
[DOI] 10.1128/AAC.05515-11.
[PMID] 22083473.
2012
Evaluation of once-daily vancomycin against methicillin-resistant Staphylococcus aureus in a hollow-fiber infection model.
Antimicrobial agents and chemotherapy.
56(2):682-6
[DOI] 10.1128/AAC.05664-11.
[PMID] 22083484.
2012
Frequentist and Bayesian pharmacometric-based approaches to facilitate critically needed new antibiotic development: overcoming lies, damn lies, and statistics.
Antimicrobial agents and chemotherapy.
56(3):1466-70
[DOI] 10.1128/AAC.01743-10.
[PMID] 22155834.
2012
Impact of spores on the comparative efficacies of five antibiotics for treatment of Bacillus anthracis in an in vitro hollow fiber pharmacodynamic model.
Antimicrobial agents and chemotherapy.
56(3):1229-39
[DOI] 10.1128/AAC.01109-10.
[PMID] 22155821.
2012
In vivo activity of oritavancin in animal infection models and rationale for a new dosing regimen in humans.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
54 Suppl 3:S220-8
[DOI] 10.1093/cid/cis001.
[PMID] 22431852.
2012
New EMA guideline for antimicrobial development.
The Lancet. Infectious diseases.
12(4):265-6
[DOI] 10.1016/S1473-3099(12)70046-4.
[PMID] 22459079.
2012
Pharmacodynamic analysis of a serine protease inhibitor, MK-4519, against hepatitis C virus using a novel in vitro pharmacodynamic system.
Antimicrobial agents and chemotherapy.
56(3):1170-81
[DOI] 10.1128/AAC.05383-11.
[PMID] 22155837.
2012
Pharmacodynamics of β-lactamase inhibition by NXL104 in combination with ceftaroline: examining organisms with multiple types of β-lactamases.
Antimicrobial agents and chemotherapy.
56(1):258-70
[DOI] 10.1128/AAC.05005-11.
[PMID] 22024819.
2012
Population pharmacokinetics of extended-infusion piperacillin-tazobactam in hospitalized patients with nosocomial infections.
Antimicrobial agents and chemotherapy.
56(8):4087-94
[DOI] 10.1128/AAC.00521-12.
[PMID] 22585219.
2012
Population pharmacokinetics of piperacillin at two dose levels: influence of nonlinear pharmacokinetics on the pharmacodynamic profile.
Antimicrobial agents and chemotherapy.
56(11):5715-23
[DOI] 10.1128/AAC.00937-12.
[PMID] 22908169.
2012
Resistance emergence mechanism and mechanism of resistance suppression by tobramycin for cefepime for Pseudomonas aeruginosa.
Antimicrobial agents and chemotherapy.
56(1):231-42
[DOI] 10.1128/AAC.05252-11.
[PMID] 22005996.
2011
Antiviral pharmacodynamics in hollow fibre bioreactors.
Antiviral chemistry & chemotherapy.
21(5):183-92
[DOI] 10.3851/IMP1770.
[PMID] 21566264.
2011
Comparative efficacies of candidate antibiotics against Yersinia pestis in an in vitro pharmacodynamic model.
Antimicrobial agents and chemotherapy.
55(6):2623-8
[DOI] 10.1128/AAC.01374-10.
[PMID] 21486959.
2011
Conserving antibiotics for the future: new ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective.
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
14(2):107-17
[DOI] 10.1016/j.drup.2011.02.005.
[PMID] 21440486.
2011
Determination of Meropenem Penetration Into the Lung From Sparse Data Reply
.
55:5959-5961
2011
Determination of meropenem penetration into the lung from Sparse data.
Antimicrobial agents and chemotherapy.
55(12):5959-61
[DOI] 10.1128/AAC.05066-11.
[PMID] 22081725.
2011
Dose range evaluation of Mycograb C28Y variant, a human recombinant antibody fragment to heat shock protein 90, in combination with amphotericin B-desoxycholate for treatment of murine systemic candidiasis.
Antimicrobial agents and chemotherapy.
55(7):3295-304
[DOI] 10.1128/AAC.01324-10.
[PMID] 21502626.
2011
Effect of administration of moxifloxacin plus rifampin against Mycobacterium tuberculosis for 7 of 7 days versus 5 of 7 days in an in vitro pharmacodynamic system.
mBio.
2(4):e00108-11
[DOI] 10.1128/mBio.00108-11.
[PMID] 21750119.
2011
Effect of half-life on the pharmacodynamic index of zanamivir against influenza virus delineated by a mathematical model.
Antimicrobial agents and chemotherapy.
55(4):1747-53
[DOI] 10.1128/AAC.01629-10.
[PMID] 21263045.
2011
Effects of sub-minimum inhibitory concentrations of ciprofloxacin on enteroaggregative Escherichia coli and the role of the surface protein dispersin.
International journal of antimicrobial agents.
38(1):27-34
[DOI] 10.1016/j.ijantimicag.2011.03.011.
[PMID] 21570813.
2011
Impact of granulocytes on the antimicrobial effect of tedizolid in a mouse thigh infection model.
Antimicrobial agents and chemotherapy.
55(11):5300-5
[DOI] 10.1128/AAC.00502-11.
[PMID] 21911576.
2011
In vivo pharmacodynamics of torezolid phosphate (TR-701), a new oxazolidinone antibiotic, against methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains in a mouse thigh infection model.
Antimicrobial agents and chemotherapy.
55(7):3453-60
[DOI] 10.1128/AAC.01565-10.
[PMID] 21502615.
2011
Meropenem penetration into epithelial lining fluid in mice and humans and delineation of exposure targets.
Antimicrobial agents and chemotherapy.
55(7):3406-12
[DOI] 10.1128/AAC.01559-10.
[PMID] 21576431.
2011
Optimization of aminoglycoside therapy.
Antimicrobial agents and chemotherapy.
55(6):2528-31
[DOI] 10.1128/AAC.01314-10.
[PMID] 21402835.
2011
Penetration of meropenem into epithelial lining fluid of patients with ventilator-associated pneumonia.
Antimicrobial agents and chemotherapy.
55(4):1606-10
[DOI] 10.1128/AAC.01330-10.
[PMID] 21300830.
2011
Penetration of vancomycin into epithelial lining fluid in healthy volunteers.
Antimicrobial agents and chemotherapy.
55(12):5507-11
[DOI] 10.1128/AAC.00712-11.
[PMID] 21911567.
2011
Pharmacodynamic modeling of anti-cancer activity of tetraiodothyroacetic acid in a perfused cell culture system.
PLoS computational biology.
7(2)
[DOI] 10.1371/journal.pcbi.1001073.
[PMID] 21304935.
2011
Pharmacokinetics and pharmacodynamics of intravenous daptomycin during continuous ambulatory peritoneal dialysis.
Clinical journal of the American Society of Nephrology : CJASN.
6(5):1081-8
[DOI] 10.2215/CJN.08510910.
[PMID] 21393490.
2011
Pharmacokinetics and pharmacodynamics: optimal antimicrobial therapy in the intensive care unit.
Critical care clinics.
27(1):1-18
[DOI] 10.1016/j.ccc.2010.11.003.
[PMID] 21144983.
2011
Refining vancomycin protein binding estimates: identification of clinical factors that influence protein binding.
Antimicrobial agents and chemotherapy.
55(9):4277-82
[DOI] 10.1128/AAC.01674-10.
[PMID] 21670191.
2011
Saturability of granulocyte kill of Pseudomonas aeruginosa in a murine model of pneumonia.
Antimicrobial agents and chemotherapy.
55(6):2693-5
[DOI] 10.1128/AAC.01687-10.
[PMID] 21422203.
2011
Use of an in vitro pharmacodynamic model to derive a moxifloxacin regimen that optimizes kill of Yersinia pestis and prevents emergence of resistance.
Antimicrobial agents and chemotherapy.
55(2):822-30
[DOI] 10.1128/AAC.00818-10.
[PMID] 21115791.
2011
Use of pharmacokinetic and pharmacodynamic principles to determine optimal administration of daptomycin in patients receiving standardized thrice-weekly hemodialysis.
Antimicrobial agents and chemotherapy.
55(4):1677-83
[DOI] 10.1128/AAC.01224-10.
[PMID] 21282429.
2011
Vancomycin: we can’t get there from here.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
52(8):969-74
[DOI] 10.1093/cid/cir078.
[PMID] 21460308.
2011
What are the properties that make an antibiotic acceptable for therapy of community-acquired pneumonia?
The Journal of antimicrobial chemotherapy.
66 Suppl 3:iii61-7
[DOI] 10.1093/jac/dkr100.
[PMID] 21482571.
2011
Zanamivir, at 600 milligrams twice daily, inhibits oseltamivir-resistant 2009 pandemic H1N1 influenza virus in an in vitro hollow-fiber infection model system.
Antimicrobial agents and chemotherapy.
55(4):1740-6
[DOI] 10.1128/AAC.01628-10.
[PMID] 21263046.
2010
Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation.
Diagnostic microbiology and infectious disease.
68(3):251-8
[DOI] 10.1016/j.diagmicrobio.2010.06.012.
[PMID] 20851549.
2010
Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
50(12):1568-74
[DOI] 10.1086/652767.
[PMID] 20462352.
2010
Determination of antibiotic dosage adjustments in patients with renal impairment: elements for success.
The Journal of antimicrobial chemotherapy.
65(11):2285-90
[DOI] 10.1093/jac/dkq323.
[PMID] 20736235.
2010
High-dose continuous infusion beta-lactam antibiotics for the treatment of resistant Pseudomonas aeruginosa infections in immunocompromised patients.
The Annals of pharmacotherapy.
44(5):929-35
[DOI] 10.1345/aph.1M717.
[PMID] 20371747.
2010
How many steps along the path is too far?
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
50(1):37-9
[DOI] 10.1086/648680.
[PMID] 19951111.
2010
Identification of optimal renal dosage adjustments for traditional and extended-infusion piperacillin-tazobactam dosing regimens in hospitalized patients.
Antimicrobial agents and chemotherapy.
54(1):460-5
[DOI] 10.1128/AAC.00296-09.
[PMID] 19858253.
2010
Impact of burden on granulocyte clearance of bacteria in a mouse thigh infection model.
Antimicrobial agents and chemotherapy.
54(10):4368-72
[DOI] 10.1128/AAC.00133-10.
[PMID] 20516275.
2010
Impact of different carbapenems and regimens of administration on resistance emergence for three isogenic Pseudomonas aeruginosa strains with differing mechanisms of resistance.
Antimicrobial agents and chemotherapy.
54(6):2638-45
[DOI] 10.1128/AAC.01721-09.
[PMID] 20308371.
2010
Impact of different factors on the probability of clinical response in tigecycline-treated patients with intra-abdominal infections.
Antimicrobial agents and chemotherapy.
54(3):1207-12
[DOI] 10.1128/AAC.00182-09.
[PMID] 20038623.
2010
In vitro system for modeling influenza A virus resistance under drug pressure.
Antimicrobial agents and chemotherapy.
54(8):3442-50
[DOI] 10.1128/AAC.01385-09.
[PMID] 20498316.
2010
Pharmacodynamics of ceftaroline fosamil for complicated skin and skin structure infection: rationale for improved anti-methicillin-resistant Staphylococcus aureus activity.
The Journal of antimicrobial chemotherapy.
65 Suppl 4:iv33-9
[DOI] 10.1093/jac/dkq253.
[PMID] 21115453.
2010
Pharmacokinetic-pharmacodynamic considerations in the design of hospital-acquired or ventilator-associated bacterial pneumonia studies: look before you leap!
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
51 Suppl 1:S103-10
[DOI] 10.1086/653057.
[PMID] 20597657.
2010
Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteers.
Antimicrobial agents and chemotherapy.
54(3):1275-82
[DOI] 10.1128/AAC.00936-09.
[PMID] 20065059.
2010
The combination of meropenem and levofloxacin is synergistic with respect to both Pseudomonas aeruginosa kill rate and resistance suppression.
Antimicrobial agents and chemotherapy.
54(6):2646-54
[DOI] 10.1128/AAC.00065-10.
[PMID] 20368395.
2010
The combination of rifampin plus moxifloxacin is synergistic for suppression of resistance but antagonistic for cell kill of Mycobacterium tuberculosis as determined in a hollow-fiber infection model.
mBio.
1(3)
[DOI] 10.1128/mBio.00139-10.
[PMID] 20802826.
2009
Antifungal pharmacokinetics and pharmacodynamics: bridging from the bench to bedside.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
15(7):602-12
[DOI] 10.1111/j.1469-0691.2009.02913.x.
[PMID] 19673971.
2009
Comparison of the pharmacokinetics and pharmacodynamic profile of carumonam in cystic fibrosis patients and healthy volunteers.
Diagnostic microbiology and infectious disease.
65(2):130-41
[DOI] 10.1016/j.diagmicrobio.2009.06.018.
[PMID] 19748423.
2009
Competitive inhibition of renal tubular secretion of gemifloxacin by probenecid.
Antimicrobial agents and chemotherapy.
53(9):3902-7
[DOI] 10.1128/AAC.01200-08.
[PMID] 19564368.
2009
Differing effects of combination chemotherapy with meropenem and tobramycin on cell kill and suppression of resistance of wild-type Pseudomonas aeruginosa PAO1 and its isogenic MexAB efflux pump-overexpressed mutant.
Antimicrobial agents and chemotherapy.
53(6):2266-73
[DOI] 10.1128/AAC.01680-08.
[PMID] 19289521.
2009
Feedback dose alteration significantly affects probability of pathogen eradication in nosocomial pneumonia.
The European respiratory journal.
34(2):394-400
[DOI] 10.1183/09031936.00149508.
[PMID] 19213786.
2009
Identifying exposure targets for treatment of staphylococcal pneumonia with ceftobiprole.
Antimicrobial agents and chemotherapy.
53(8):3294-301
[DOI] 10.1128/AAC.00144-09.
[PMID] 19451287.
2009
Impact of short-course quinolone therapy on susceptible and resistant populations of Staphylococcus aureus.
The Journal of infectious diseases.
199(2):219-26
[DOI] 10.1086/595739.
[PMID] 19049435.
2009
Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
Antimicrobial agents and chemotherapy.
53(11):4718-25
[DOI] 10.1128/AAC.00802-09.
[PMID] 19687233.
2009
L-Thyroxine vs. 3,5,3′-triiodo-L-thyronine and cell proliferation: activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase.
American journal of physiology. Cell physiology.
296(5):C980-91
[DOI] 10.1152/ajpcell.00305.2008.
[PMID] 19158403.
2009
Meropenem pharmacokinetics in the newborn.
Antimicrobial agents and chemotherapy.
53(9):3871-9
[DOI] 10.1128/AAC.00351-09.
[PMID] 19581463.
2009
Penetration of moxifloxacin into bone evaluated by Monte Carlo simulation.
Antimicrobial agents and chemotherapy.
53(5):2074-81
[DOI] 10.1128/AAC.01056-08.
[PMID] 19223648.
2009
Pharmacodynamics of cidofovir for vaccinia virus infection in an in vitro hollow-fiber infection model system.
Antimicrobial agents and chemotherapy.
53(1):129-35
[DOI] 10.1128/AAC.00708-08.
[PMID] 18852271.
2009
Pharmacodynamics of levofloxacin in a murine pneumonia model of Pseudomonas aeruginosa infection: determination of epithelial lining fluid targets.
Antimicrobial agents and chemotherapy.
53(8):3325-30
[DOI] 10.1128/AAC.00006-09.
[PMID] 19364849.
2009
Prediction of the pharmacodynamically linked variable of oseltamivir carboxylate for influenza A virus using an in vitro hollow-fiber infection model system.
Antimicrobial agents and chemotherapy.
53(6):2375-81
[DOI] 10.1128/AAC.00167-09.
[PMID] 19364864.
2009
Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
49(4):507-14
[DOI] 10.1086/600884.
[PMID] 19586413.
2008
Is 60 days of ciprofloxacin administration necessary for postexposure prophylaxis for Bacillus anthracis?
Antimicrobial agents and chemotherapy.
52(11):3973-9
[DOI] 10.1128/AAC.00453-08.
[PMID] 18725437.
2008
Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity.
Antimicrobial agents and chemotherapy.
52(4):1330-6
[DOI] 10.1128/AAC.01602-07.
[PMID] 18227177.
2008
Modeling amantadine treatment of influenza A virus in vitro.
Journal of theoretical biology.
254(2):439-51
[DOI] 10.1016/j.jtbi.2008.05.031.
[PMID] 18653201.
2008
Pharmacokinetics-pharmacodynamics of quinolones against Streptococcus pneumoniae in patients with community-acquired pneumonia.
Diagnostic microbiology and infectious disease.
62(1):99-101
[DOI] 10.1016/j.diagmicrobio.2008.04.008.
[PMID] 18583085.
2008
Population pharmacokinetics of micafungin in adult patients.
Diagnostic microbiology and infectious disease.
60(3):329-31
[PMID] 18024052.
2008
Telavancin penetration into human epithelial lining fluid determined by population pharmacokinetic modeling and Monte Carlo simulation.
Antimicrobial agents and chemotherapy.
52(7):2300-4
[DOI] 10.1128/AAC.01110-07.
[PMID] 18426898.
2008
The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates.
The Journal of infectious diseases.
197(1):163-71
[DOI] 10.1086/524063.
[PMID] 18171300.
2008
Use of an in vitro pharmacodynamic model to derive a linezolid regimen that optimizes bacterial kill and prevents emergence of resistance in Bacillus anthracis.
Antimicrobial agents and chemotherapy.
52(7):2486-96
[DOI] 10.1128/AAC.01439-07.
[PMID] 18458134.
2008
Use of pharmacodynamic endpoints for the evaluation of levofloxacin for the treatment of acute maxillary sinusitis.
Diagnostic microbiology and infectious disease.
61(1):13-20
[DOI] 10.1016/j.diagmicrobio.2008.01.010.
[PMID] 18313879.
2008
Use of population pharmacokinetic modeling and Monte Carlo simulation to describe the pharmacodynamic profile of cefditoren in plasma and epithelial lining fluid.
Antimicrobial agents and chemotherapy.
52(6):1945-51
[PMID] 17485507.
2007
Back to the future: using aminoglycosides again and how to dose them optimally.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
45(6):753-60
[PMID] 17712761.
2007
Comparison of 2 antibiotics that inhibit protein synthesis for the treatment of infection with Yersinia pestis delivered by aerosol in a mouse model of pneumonic plague.
The Journal of infectious diseases.
196(5):782-7
[PMID] 17674322.
2007
Comparison of the probability of target attainment between ceftriaxone and cefepime in the cerebrospinal fluid and serum against Streptococcus pneumoniae.
Diagnostic microbiology and infectious disease.
58(4):445-52
[PMID] 17512154.
2007
Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin.
Antimicrobial agents and chemotherapy.
51(11):3781-8
[PMID] 17724157.
2007
Effect of neutropenia and treatment delay on the response to antifungal agents in experimental disseminated candidiasis.
Antimicrobial agents and chemotherapy.
51(1):285-95
[PMID] 17088486.
2007
Evaluation of tigecycline penetration into colon wall tissue and epithelial lining fluid using a population pharmacokinetic model and Monte Carlo simulation.
Antimicrobial agents and chemotherapy.
51(11):4085-9
[PMID] 17846139.
2007
Impact of drug-exposure intensity and duration of therapy on the emergence of Staphylococcus aureus resistance to a quinolone antimicrobial.
The Journal of infectious diseases.
195(12):1818-27
[PMID] 17492598.
2007
Impact of resistance selection and mutant growth fitness on the relative efficacies of streptomycin and levofloxacin for plague therapy.
Antimicrobial agents and chemotherapy.
51(8):2661-7
[PMID] 17517837.
2007
In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae.
Antimicrobial agents and chemotherapy.
51(11):3988-4000
[PMID] 17846144.
2007
Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations.
Antimicrobial agents and chemotherapy.
51(7):2329-36
[PMID] 17438043.
2007
Isoniazid’s bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growth.
The Journal of infectious diseases.
195(2):194-201
[PMID] 17191164.
2007
Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia.
Antimicrobial agents and chemotherapy.
51(3):968-74
[PMID] 17194830.
2007
Optimization of the dosage of flucytosine in combination with amphotericin B for disseminated candidiasis: a pharmacodynamic rationale for reduced dosing.
Antimicrobial agents and chemotherapy.
51(10):3760-2
[PMID] 17682101.
2007
Pathogenesis of Aspergillus fumigatus and the kinetics of galactomannan in an in vitro model of early invasive pulmonary aspergillosis: implications for antifungal therapy.
The Journal of infectious diseases.
195(3):455-66
[PMID] 17205486.
2007
Pharmacodynamics of ceftazidime and meropenem in cerebrospinal fluid: results of population pharmacokinetic modelling and Monte Carlo simulation.
The Journal of antimicrobial chemotherapy.
60(5):1038-44
[PMID] 17785282.
2007
Pharmacokinetics and pharmacodynamics of antimicrobials.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
45 Suppl 1:S89-95
[PMID] 17582578.
2007
Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it’s not just for mice anymore.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
44(1):79-86
[PMID] 17143821.
2007
Pharmacokinetics-pharmacodynamics of gatifloxacin in a lethal murine Bacillus anthracis inhalation infection model.
Antimicrobial agents and chemotherapy.
51(12):4351-5
[PMID] 17875992.
2007
Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
44(3):357-63
[PMID] 17205441.
2007
Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial.
Antimicrobial agents and chemotherapy.
51(9):3304-10
[PMID] 17620371.
2007
Population pharmacokinetics at two dose levels and pharmacodynamic profiling of flucloxacillin.
Antimicrobial agents and chemotherapy.
51(9):3290-7
[PMID] 17576847.
2007
Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing.
Antimicrobial agents and chemotherapy.
51(10):3714-9
[PMID] 17638696.
2007
Prevalence of drug-resistant and nonsubtype B HIV strains in antiretroviral-naïve, HIV-infected individuals in New York State.
AIDS patient care and STDs.
21(9):644-52
[PMID] 17919091.
2007
Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects.
Antimicrobial agents and chemotherapy.
51(7):2378-87
[PMID] 17387149.
2007
Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers.
Antimicrobial agents and chemotherapy.
51(7):2497-507
[PMID] 17485505.
2007
The relationship between quinolone exposures and resistance amplification is characterized by an inverted U: a new paradigm for optimizing pharmacodynamics to counterselect resistance.
Antimicrobial agents and chemotherapy.
51(2):744-7
[PMID] 17116679.
2006
Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis.
Antimicrobial agents and chemotherapy.
50(11):3695-700
[PMID] 16954319.
2006
Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists.
Pharmacotherapy.
26(9):1320-32
[PMID] 16945055.
2006
Clinical research in the lay press: irresponsible journalism raises a huge dose of doubt.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
43(8):1031-9
[PMID] 16983616.
2006
Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal-weight, obese, and extremely obese adults.
Antimicrobial agents and chemotherapy.
50(4):1222-7
[PMID] 16569832.
2006
Derivation of an in vivo drug exposure breakpoint for flucytosine against Candida albicans and Impact of the MIC, growth rate, and resistance genotype on the antifungal effect.
Antimicrobial agents and chemotherapy.
50(11):3680-8
[PMID] 16954320.
2006
Pharmacodynamic profiling of cefepime in plasma and cerebrospinal fluid of hospitalized patients with external ventriculostomies.
Diagnostic microbiology and infectious disease.
54(3):223-30
[PMID] 16423490.
2006
Pharmacokinetic considerations and efficacy of levofloxacin in an inhalational anthrax (postexposure) rhesus monkey model.
Antimicrobial agents and chemotherapy.
50(11):3535-42
[PMID] 17065619.
2006
Population pharmacokinetic modeling and Monte Carlo simulation of varying doses of intravenous metronidazole.
Diagnostic microbiology and infectious disease.
55(4):303-9
[PMID] 16887471.
2006
Quinolone efflux pumps play a central role in emergence of fluoroquinolone resistance in Streptococcus pneumoniae.
Antimicrobial agents and chemotherapy.
50(1):310-7
[PMID] 16377702.
2006
Sex differences in CYP3A activity using intravenous and oral midazolam.
Clinical pharmacology and therapeutics.
80(5):531-8
[PMID] 17112809.
2006
The crisis of resistance: identifying drug exposures to suppress amplification of resistant mutant subpopulations.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
42(4):525-32
[PMID] 16421797.
2005
Bacterial-population responses to drug-selective pressure: examination of garenoxacin’s effect on Pseudomonas aeruginosa.
The Journal of infectious diseases.
192(3):420-8
[PMID] 15995955.
2005
Effective antimicrobial regimens for use in humans for therapy of Bacillus anthracis infections and postexposure prophylaxis.
Antimicrobial agents and chemotherapy.
49(12):5099-106
[PMID] 16304178.
2005
Evaluation by monte carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers.
Antimicrobial agents and chemotherapy.
49(5):1881-9
[PMID] 15855510.
2005
Explaining the poor bacteriologic eradication rate of single-dose ceftriaxone in group a streptococcal tonsillopharyngitis: a reverse engineering solution using pharmacodynamic modeling.
Pediatrics.
116(4):927-32
[PMID] 16199703.
2005
Infection site concentrations: their therapeutic importance and the macrolide and macrolide-like class of antibiotics.
Pharmacotherapy.
25(12 Pt 2):150S-158S
[PMID] 16305286.
2005
Pharmacodynamic evaluation of extending the administration time of meropenem using a Monte Carlo simulation.
Antimicrobial agents and chemotherapy.
49(1):461-3
[PMID] 15616337.
2005
Pharmacodynamic evidence that ciprofloxacin failure against tuberculosis is not due to poor microbial kill but to rapid emergence of resistance.
Antimicrobial agents and chemotherapy.
49(8):3178-81
[PMID] 16048921.
2005
Pharmacodynamics of an 800-mg dose of telithromycin in patients with community-acquired pneumonia caused by extracellular pathogens.
Diagnostic microbiology and infectious disease.
52(1):45-52
[PMID] 15878442.
2005
Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity.
Antimicrobial agents and chemotherapy.
49(12):5058-68
[PMID] 16304173.
2005
Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update.
The Journal of antimicrobial chemotherapy.
55(5):601-7
[PMID] 15772142.
2005
Surface response modeling to examine the combination of amphotericin B deoxycholate and 5-fluorocytosine for treatment of invasive candidiasis.
The Journal of infectious diseases.
192(4):673-80
[PMID] 16028137.
2004
A 48-week duration of therapy with pegylated interferon alpha 2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C virus.
The Journal of infectious diseases.
189(6):964-70
[PMID] 14999598.
2004
Antimicrobial pharmacodynamics: critical interactions of ‘bug and drug’.
Nature reviews. Microbiology.
2(4):289-300
[PMID] 15031728.
2004
How does a patient maximally benefit from anti-infective chemotherapy?
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
39(8):1245-6
[PMID] 15486851.
2004
Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem.
Clinical therapeutics.
26(8):1187-98
[PMID] 15476901.
2004
Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation.
Antimicrobial agents and chemotherapy.
48(12):4718-24
[PMID] 15561849.
2004
Phenotypic drug susceptibility assay for influenza virus neuraminidase inhibitors.
Clinical and diagnostic laboratory immunology.
11(1):21-8
[PMID] 14715540.
2004
Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia.
The Journal of infectious diseases.
189(9):1590-7
[PMID] 15116294.
2004
Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling.
The Journal of infectious diseases.
190(9):1642-51
[PMID] 15478070.
2003
Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy.
The Journal of clinical investigation.
112(2):275-85
[PMID] 12865415.
2003
Comparative pharmacokinetic analysis by standard two-stage method versus nonparametric population modeling.
Pharmacotherapy.
23(12):1545-9
[PMID] 14695034.
2003
Guillain-Barré syndrome associated with immune reconstitution.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
36(9):e111-4
[PMID] 12715328.
2003
In vitro-in vivo model for evaluating the antiviral activity of amprenavir in combination with ritonavir administered at 600 and 100 milligrams, respectively, every 12 hours.
Antimicrobial agents and chemotherapy.
47(11):3393-9
[PMID] 14576093.
2003
Integration of population pharmacokinetics, a pharmacodynamic target, and microbiologic surveillance data to generate a rational empiric dosing strategy for cefepime against Pseudomonas aeruginosa.
Pharmacotherapy.
23(3):291-5
[PMID] 12627925.
2003
Optimal sampling schedule design for populations of patients.
Antimicrobial agents and chemotherapy.
47(9):2888-91
[PMID] 12936990.
2003
Pharmacodynamics and clinical use of anti-HIV drugs.
Infectious disease clinics of North America.
17(3):651-74
[PMID] 14711082.
2003
Pharmacokinetics and pharmacodynamics of cefepime in patients with various degrees of renal function.
Antimicrobial agents and chemotherapy.
47(6):1853-61
[PMID] 12760858.
2003
Predicting efficacy of antiinfectives with pharmacodynamics and Monte Carlo simulation.
The Pediatric infectious disease journal.
22(11):982-92; quiz 993
[PMID] 14614372.
2003
Prevention of resistance: a goal for dose selection for antimicrobial agents.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
36(Suppl 1):S42-50
[PMID] 12516029.
2002
Dose proportional inhibition of HIV-1 replication by mycophenolic acid and synergistic inhibition in combination with abacavir, didanosine, and tenofovir.
Antiviral research.
55(1):41-52
[PMID] 12076750.
2002
Levofloxacin penetration into epithelial lining fluid as determined by population pharmacokinetic modeling and monte carlo simulation.
Antimicrobial agents and chemotherapy.
46(2):586-9
[PMID] 11796385.
2002
Pharmacodynamics of abacavir in an in vitro hollow-fiber model system.
Antimicrobial agents and chemotherapy.
46(2):464-70
[PMID] 11796359.
2001
Fluoroquinolone pharmacodynamics.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
33(12):2091-6
[PMID] 11712099.
2001
Hollow-fiber unit evaluation of a new human immunodeficiency virus type 1 protease inhibitor, BMS-232632, for determination of the linked pharmacodynamic variable.
The Journal of infectious diseases.
183(7):1126-9
[PMID] 11237841.
2001
Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection.
Antimicrobial agents and chemotherapy.
45(3):845-51
[PMID] 11181370.
2001
Susceptibilities of human cytomegalovirus clinical isolates to BAY38-4766, BAY43-9695, and ganciclovir.
Antimicrobial agents and chemotherapy.
45(10):2925-7
[PMID] 11557492.
2001
Tolerance and pharmacokinetic interactions of rifabutin and azithromycin.
Antimicrobial agents and chemotherapy.
45(5):1572-7
[PMID] 11302832.
2001
Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint.
Antimicrobial agents and chemotherapy.
45(1):13-22
[PMID] 11120938.
2000
A population pharmacokinetic analysis of the penetration of the prostate by levofloxacin.
Antimicrobial agents and chemotherapy.
44(8):2046-51
[PMID] 10898674.
2000
Evaluation of an antiseptic triple-lumen catheter in an intensive care unit.
Critical care medicine.
28(2):366-70
[PMID] 10708168.
2000
Fluoroquinolone pharmacodynamics: prospective determination of relationships between exposure and outcome.
Journal of chemotherapy (Florence, Italy).
12 Suppl 4:21-6
[PMID] 11131956.
2000
Meropenem: clinical response in relation to in vitro susceptibility.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
6(4):185-94
[PMID] 11168106.
2000
The triple combination indinavir-zidovudine-lamivudine is highly synergistic.
Antimicrobial agents and chemotherapy.
44(4):1051-8
[PMID] 10722511.
2000
Use of drug effect interaction modeling with Monte Carlo simulation to examine the impact of dosing interval on the projected antiviral activity of the combination of abacavir and amprenavir.
Antimicrobial agents and chemotherapy.
44(6):1655-9
[PMID] 10817724.
1999
Correlation of quantitative bone marrow and blood cultures in AIDS patients with disseminated Mycobacterium avium complex infection.
The Journal of infectious diseases.
180(2):438-47
[PMID] 10395860.
1999
Daptomycin: a novel agent for Gram-positive infections.
Expert opinion on investigational drugs.
8(8):1223-38
[PMID] 15992147.
1999
Efficacies of high-dose fluconazole plus amphotericin B and high-dose fluconazole plus 5-fluorocytosine versus amphotericin B, fluconazole, and 5-fluorocytosine monotherapies in treatment of experimental endocarditis, endophthalmitis, and pyelonephritis due to Candida albicans.
Antimicrobial agents and chemotherapy.
43(12):2831-40
[PMID] 10582868.
1999
Interaction between fluconazole and amphotericin B in mice with systemic infection due to fluconazole-susceptible or -resistant strains of Candida albicans.
Antimicrobial agents and chemotherapy.
43(12):2841-7
[PMID] 10582869.
1999
Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria.
Antimicrobial agents and chemotherapy.
43(3):623-9
[PMID] 10049277.
1999
Pharmacokinetics and absolute bioavailability of ribavirin in healthy volunteers as determined by stable-isotope methodology.
Antimicrobial agents and chemotherapy.
43(10):2451-6
[PMID] 10508023.
1999
Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity.
Antimicrobial agents and chemotherapy.
43(7):1549-55
[PMID] 10390201.
1999
The safety and efficacy of granulocyte-macrophage colony-stimulating factor (Sargramostim) added to indinavir- or ritonavir-based antiretroviral therapy: a randomized double-blind, placebo-controlled trial.
The Journal of infectious diseases.
180(4):1064-71
[PMID] 10479132.
1998
Factors influencing the emergence of resistance to indinavir: role of virologic, immunologic, and pharmacologic variables.
The Journal of infectious diseases.
178(2):360-7
[PMID] 9697715.
1998
Flow cytometric determination of ganciclovir susceptibilities of human cytomegalovirus clinical isolates.
Journal of clinical microbiology.
36(4):958-64
[PMID] 9542916.
1998
Infection in the intensive care unit: beta-lactamase-mediated resistance among Enterobacteriaceae and optimal antimicrobial dosing.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
27 Suppl 1:S111-6
[PMID] 9710679.
1998
Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection.
Antimicrobial agents and chemotherapy.
42(5):1098-104
[PMID] 9593134.
1998
Mathematical modeling of the interrelationship of CD4 lymphocyte count and viral load changes induced by the protease inhibitor indinavir.
Antimicrobial agents and chemotherapy.
42(2):358-61
[PMID] 9527786.
1998
Nucleoside analog 1592U89 and human immunodeficiency virus protease inhibitor 141W94 are synergistic in vitro.
Antimicrobial agents and chemotherapy.
42(9):2153-9
[PMID] 9736527.
1998
Pharmacodynamics of fluconazole in a murine model of systemic candidiasis.
Antimicrobial agents and chemotherapy.
42(5):1105-9
[PMID] 9593135.
1998
Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials.
JAMA.
279(2):125-9
[PMID] 9440662.
1998
Pharmacokinetic studies of fluconazole in rabbits characterizing doses which achieve peak levels in serum and area under the concentration-time curve values which mimic those of high-dose fluconazole in humans.
Antimicrobial agents and chemotherapy.
42(6):1512-4
[PMID] 9624506.
1998
Pharmacokinetics and pharmacodynamics of fluoroquinolones.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
4 Suppl 2:S27-S41
[PMID] 11869252.
1998
Pharmacokinetics of sparfloxacin in the serum and vitreous humor of rabbits: physicochemical properties that regulate penetration of quinolone antimicrobials.
Antimicrobial agents and chemotherapy.
42(6):1417-23
[PMID] 9624487.
1998
Rapid ganciclovir susceptibility assay using flow cytometry for human cytomegalovirus clinical isolates.
Antimicrobial agents and chemotherapy.
42(9):2326-31
[PMID] 9736557.
1998
Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.
Antimicrobial agents and chemotherapy.
42(3):631-9
[PMID] 9517944.
1997
Comparative pharmacokinetics and renal effects of cyclosporin A and cyclosporin G in renal allograft recipients.
Journal of clinical pharmacology.
37(7):575-86
[PMID] 9243350.
1997
Meropenem: laboratory and clinical data.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
3 Suppl 4:S51-S59
[PMID] 11869241.
1997
Modeling of the change in CD4 lymphocyte counts in patients before and after administration of the human immunodeficiency virus protease inhibitor indinavir.
Antimicrobial agents and chemotherapy.
41(2):449-53
[PMID] 9021206.
1997
Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections.
Journal of chemotherapy (Florence, Italy).
9 Suppl 3:38-44
[PMID] 9248979.
1996
A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir).
AIDS (London, England).
10(5):485-92
[PMID] 8724039.
1996
Acute thrombocytopenia secondary to the administration of the peptidomimetic HIV protease inhibitor MK-639(L735524).
AIDS (London, England).
10(6):678-80
[PMID] 8780825.
1996
Aqueous and vitreous penetration of ciprofloxacin following different modes of systemic administration.
Experimental eye research.
63(2):129-36
[PMID] 8983970.
1996
Comparative pharmacokinetics of cyclosporine A and cyclosporine G in renal allograft recipients.
Transplantation proceedings.
28(2)
[PMID] 8623449.
1996
Human serum alpha 1 acid glycoprotein reduces uptake, intracellular concentration, and antiviral activity of A-80987, an inhibitor of the human immunodeficiency virus type 1 protease.
Antimicrobial agents and chemotherapy.
40(6):1491-7
[PMID] 8726025.
1996
Modeling combinations of antiretroviral agents in vitro with integration of pharmacokinetics: guidance in regimen choice for clinical trial evaluation.
Antimicrobial agents and chemotherapy.
40(5):1143-7
[PMID] 8723455.
1996
Nonparametric expectation maximization population modeling of ganciclovir.
Journal of clinical pharmacology.
36(4):301-10
[PMID] 8728343.
1996
Relationship between foscarnet exposure, baseline cytomegalovirus (CMV) blood culture and the time to progression of CMV retinitis in HIV-positive patients.
AIDS (London, England).
10(10):1113-9
[PMID] 8874628.
1996
Relevance of plasma protein binding to antiviral activity and clinical efficacy of inhibitors of human immunodeficiency virus protease.
The Journal of infectious diseases.
173(6):1524-6
[PMID] 8648237.
1996
Relevance of the Alexander Project: pharmacodynamic considerations.
The Journal of antimicrobial chemotherapy.
38 Suppl A:141-54
[PMID] 8858480.
1996
Soluble tumor necrosis factor-alpha receptor type II (sTNF alpha RII) correlates with human immunodeficiency virus (HIV) RNA copy number in HIV-infected patients.
The Journal of infectious diseases.
173(2):464-7
[PMID] 8568313.
1995
Determination of robust ocular pharmacokinetic parameters in serum and vitreous humor of albino rabbits following systemic administration of ciprofloxacin from sparse data sets by using IT2S, a population pharmacokinetic modeling program.
Antimicrobial agents and chemotherapy.
39(8):1683-7
[PMID] 7486900.
1995
Efficacy of constant infusion of A-77003, an inhibitor of the human immunodeficiency virus type 1 (HIV-1) protease, in limiting acute HIV-1 infection in vitro.
Antimicrobial agents and chemotherapy.
39(11):2523-7
[PMID] 8585738.
1995
Pharmacokinetics of ofloxacin in serum and vitreous humor of albino and pigmented rabbits.
Antimicrobial agents and chemotherapy.
39(7):1493-8
[PMID] 7492092.
1995
Population differences in ganciclovir clearance as determined by nonlinear mixed-effects modelling.
Antimicrobial agents and chemotherapy.
39(10):2350-2
[PMID] 8619596.
1995
Reduction of the in vitro activity of A77003, an inhibitor of human immunodeficiency virus protease, by human serum alpha 1 acid glycoprotein.
The Journal of infectious diseases.
171(3):546-51
[PMID] 7876599.
1995
The pharmacokinetics of meropenem.
Scandinavian journal of infectious diseases. Supplementum.
96:11-6
[PMID] 7652497.
1994
Effect of 2′,3′-didehydro-3′-deoxythymidine in an in vitro hollow-fiber pharmacodynamic model system correlates with results of dose-ranging clinical studies.
Antimicrobial agents and chemotherapy.
38(6):1386-91
[PMID] 8092842.
1994
Impact of dosing schedule upon suppression of a retrovirus in a murine model of AIDS encephalopathy.
Antimicrobial agents and chemotherapy.
38(3):628-31
[PMID] 8203866.
1994
Quantitative relationships between zidovudine exposure and efficacy and toxicity.
Antimicrobial agents and chemotherapy.
38(8):1726-31
[PMID] 7986002.
1993
Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis.
Antimicrobial agents and chemotherapy.
37(3):483-90
[PMID] 8384815.
1993
Preclinical evaluation of antiviral activity and toxicity of Abbott A77003, an inhibitor of the human immunodeficiency virus type 1 protease.
Antimicrobial agents and chemotherapy.
37(1):115-9
[PMID] 8431007.
1993
Serum inhibitory and bactericidal activity against methicillin-resistant Staphylococcus aureus in volunteers receiving novobiocin and rifampin alone and in combination.
Diagnostic microbiology and infectious disease.
17(2):135-42
[PMID] 8243034.
1993
Use of human renal proximal tubule cell cultures for studying foscarnet-induced nephrotoxicity in vitro.
Antimicrobial agents and chemotherapy.
37(11):2496-9
[PMID] 8285643.
1992
Evaluation of new anti-infective drugs for the treatment of infective endocarditis. Infectious Diseases Society of America and the Food and Drug Administration.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
15 Suppl 1:S89-95
[PMID] 1477254.
1992
Impact of bioavailability on determination of the maximal tolerated dose of 2′,3′-dideoxyinosine in phase I trials.
Antimicrobial agents and chemotherapy.
36(6):1280-3
[PMID] 1416828.
1991
Optimal sampling theory and population modelling: application to determination of the influence of the microgravity environment on drug distribution and elimination.
Journal of clinical pharmacology.
31(10):962-7
[PMID] 1761728.
1990
Effect of renal function on the bioavailability of ciprofloxacin.
Antimicrobial agents and chemotherapy.
34(6):1031-4
[PMID] 2393263.
1990
Human pharmacodynamics of beta-lactams, aminoglycosides and their combination.
Scandinavian journal of infectious diseases. Supplementum.
74:235-48
[PMID] 2097712.
1990
Population pharmacokinetics of zidovudine. The Veterans Administration Cooperative Studies Group.
Clinical pharmacology and therapeutics.
48(2):161-7
[PMID] 2199132.
1989
A prospective evaluation of optimal sampling theory in the determination of the steady-state pharmacokinetics of piperacillin in febrile neutropenic cancer patients.
Clinical pharmacology and therapeutics.
45(6):635-41
[PMID] 2659235.
1989
Emergence of resistance to carbapenem antibiotics in Pseudomonas aeruginosa.
The Journal of antimicrobial chemotherapy.
24 Suppl A:161-7
[PMID] 2509413.
1989
Pharmacokinetic evaluation of two dosage regimens of clindamycin phosphate.
Antimicrobial agents and chemotherapy.
33(5):618-20
[PMID] 2751277.
1989
Prospective use of optimal sampling theory: steady-state ciprofloxacin pharmacokinetics in critically ill trauma patients.
Clinical pharmacology and therapeutics.
46(4):451-7
[PMID] 2791447.
1989
Pseudomonas meningitis therapy recommendation questioned.
Pediatrics.
83(4 Pt 2):632-3
[PMID] 2648308.
1988
An evaluation of optimal sampling strategy and adaptive study design.
Clinical pharmacology and therapeutics.
44(2):232-8
[PMID] 3293877.
1988
Efficacy of ciprofloxacin in the treatment of chronic typhoid carriers.
The Journal of infectious diseases.
157(6):1235-9
[PMID] 3373023.
1988
Relationships between renal function and disposition of oral ciprofloxacin.
Antimicrobial agents and chemotherapy.
32(10):1537-40
[PMID] 3190182.
1988
Role of pharmacokinetics in the outcome of infections.
Antimicrobial agents and chemotherapy.
32(3):289-97
[PMID] 3284456.
1987
Bactericidal activity of ciprofloxacin compared with that of cefotaxime in normal volunteers.
Antimicrobial agents and chemotherapy.
31(8):1177-82
[PMID] 3631942.
1987
Effect of dose size on bioavailability of ciprofloxacin.
Antimicrobial agents and chemotherapy.
31(6):956-8
[PMID] 3619432.
1987
Emergence of resistance to imipenem in Pseudomonas aeruginosa.
Antimicrobial agents and chemotherapy.
31(12):1892-6
[PMID] 3125787.
1987
Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function.
Antimicrobial agents and chemotherapy.
31(6):860-4
[PMID] 3619418.
1987
Steady-state pharmacokinetics of imipenem in febrile neutropenic cancer patients.
Antimicrobial agents and chemotherapy.
31(9):1420-2
[PMID] 3479047.
1987
Synergism of the combinations of imipenem plus ciprofloxacin and imipenem plus amikacin against Pseudomonas aeruginosa and other bacterial pathogens.
Antimicrobial agents and chemotherapy.
31(4):632-4
[PMID] 3111357.
1986
A double beta-lactam combination versus an aminoglycoside-containing regimen as empiric antibiotic therapy for febrile granulocytopenic cancer patients.
The American journal of medicine.
80(5C):101-11
[PMID] 3521269.
1986
Absolute oral bioavailability of ciprofloxacin.
Antimicrobial agents and chemotherapy.
30(3):444-6
[PMID] 3777908.
1986
An overview of the pharmacology of imipenem/cilastatin.
The Journal of antimicrobial chemotherapy.
18 Suppl E:79-92
[PMID] 3546249.
1986
Correlation of predicted serum bactericidal activities and values measured in volunteers.
European journal of clinical microbiology.
5(1):88-92
[PMID] 3084247.
1986
Dose ranging study and constant infusion evaluation of ciprofloxacin.
Antimicrobial agents and chemotherapy.
30(3):440-3
[PMID] 3777907.
1986
Double-blind, prospective, multicenter trial comparing ceftazidime with moxalactam in the treatment of serious gram-negative infections.
Antimicrobial agents and chemotherapy.
30(1):90-5
[PMID] 3530128.
1986
Imipenem coadministered with cilastatin compared with moxalactam: integration of serum pharmacokinetics and microbiologic activity following single-dose administration to normal volunteers.
Antimicrobial agents and chemotherapy.
29(3):412-7
[PMID] 3459390.
1986
Serum bactericidal test in volunteers–a review.
European journal of clinical microbiology.
5(1):71-8
[PMID] 3084246.
1986
Steady-state serum pharmacokinetics of novobiocin and rifampin alone and in combination.
Antimicrobial agents and chemotherapy.
30(1):42-5
[PMID] 3752982.
1985
Comparative pharmacokinetics and serum bactericidal activity of mezlocillin, ticarcillin and piperacillin, with and without gentamicin.
The Journal of antimicrobial chemotherapy.
15(5):597-606
[PMID] 4008387.
1985
In vitro susceptibility of pathogenic Vibrio species to norfloxacin and six other antimicrobial agents.
Antimicrobial agents and chemotherapy.
28(3):442-5
[PMID] 4073866.
1985
Multiple-dose ciprofloxacin dose ranging and kinetics.
Clinical pharmacology and therapeutics.
37(6):633-7
[PMID] 3159530.
1985
Multiple-dose pharmacokinetics of ciprofloxacin administered intravenously to normal volunteers.
Antimicrobial agents and chemotherapy.
28(2):235-9
[PMID] 2939794.
1985
Pharmacokinetic profile of imipenem/cilastatin in normal volunteers.
The American journal of medicine.
78(6A):47-53
[PMID] 3859215.
1985
Pharmacokinetics of ceftazidime, alone or in combination with piperacillin or tobramycin, in the sera of cancer patients.
Antimicrobial agents and chemotherapy.
27(4):605-7
[PMID] 3890730.
1985
Potential of imipenem as single-agent empiric antibiotic therapy of febrile neutropenic patients with cancer.
The American journal of medicine.
78(6A):62-72
[PMID] 3859217.
1985
Safety and tolerability of multiple doses of imipenem/cilastatin.
Clinical pharmacology and therapeutics.
37(5):539-43
[PMID] 3886256.
1984
Bactericidal activity of ceftazidime in serum compared with that of ticarcillin combined with amikacin.
Antimicrobial agents and chemotherapy.
26(3):339-42
[PMID] 6439114.
1984
Comparison of the pharmacokinetics of ceftazidime and moxalactam and their microbiological correlates in volunteers.
Antimicrobial agents and chemotherapy.
26(3):388-93
[PMID] 6391372.
1984
Effect of saturable clearance during high-dose mezlocillin therapy.
Antimicrobial agents and chemotherapy.
26(5):686-8
[PMID] 6517555.
1984
Improved micromethod for mezlocillin quantitation in serum and urine by high-pressure liquid chromatography.
Antimicrobial agents and chemotherapy.
26(5):775-7
[PMID] 6517560.
1984
Integration of selected pharmacologic and microbiologic properties of three new beta-lactam antibiotics: a hypothesis for rational comparison.
Reviews of infectious diseases.
6(3):357-63
[PMID] 6330835.
1984
Multiple-dose pharmacokinetics of imipenem-cilastatin.
Antimicrobial agents and chemotherapy.
26(5):715-21
[PMID] 6595963.
1984
Postantibiotic effect of imipenem on Pseudomonas aeruginosa.
Antimicrobial agents and chemotherapy.
26(5):678-82
[PMID] 6440477.
1984
The acylampicillins: mezlocillin, piperacillin, and azlocillin.
Reviews of infectious diseases.
6(1):13-32
[PMID] 6369480.
1984
The plasma pharmacokinetics of high dose (1 g) imipenem coadministered with 1 g cilastatin in six normal volunteers.
European journal of clinical microbiology.
3(5):468-70
[PMID] 6594235.
1984
The serum bactericidal activity of latamoxef (moxalactam), cefoperazone and cefotaxime.
The Journal of antimicrobial chemotherapy.
14(5):491-7
[PMID] 6096348.
1982
A prospective randomized controlled trial of cefoxitin versus clindamycin-aminoglycoside in mixed anaerobic-aerobic infections.
Surgery, gynecology & obstetrics.
154(5):715-20
[PMID] 7041297.
1981
Cefoxitin-resistant facultative or aerobic gram-negative bacilli in infections associated with the gastrointestinal tract.
Annals of internal medicine.
94(4 pt 1):487-8
[PMID] 7212506.
1981
Effect of carbon dioxide and pH on susceptibility of Bacteroides fragilis group to erythromycin.
Antimicrobial agents and chemotherapy.
19(2):335-6
[PMID] 6812492.
1981
Lactobacillus prophylaxis for diarrhea due to enterotoxigenic Escherichia coli.
Antimicrobial agents and chemotherapy.
20(1):104-8
[PMID] 6792978.
Grants
Jan 2023
ACTIVE
Optimizing Multi-drug Mycobacterium tuberculosis Therapy for Rapid Sterilization and Resistance Suppression
Role: Principal Investigator
Funding: NATL INST OF HLTH NIAID
Sep 2022
ACTIVE
Battelle Accelerated Therapeutics for the Treatment of Emerging and Multidrug-Resistant Bacteria (BAT-TEAM)
Role: Co-Investigator
Funding: BATTELLE MEMORIAL INST
via DEFENSE THREAT REDUCTION AGENCY
Jul 2022
ACTIVE
Development of a PO-administered beta-lactam-tarocin combination agent to treat methicillin susceptible and methicillin resistant staphylococci.
Role: Co-Investigator
Funding: PROKARYOTICS
via NATL INST OF HLTH NIAID
Aug 2021
– Aug 2022
Pharmacokinetic-Pharmacodynamic Studies to Support Dose Selection for Tebipenem for the Treatment of Mycobacterium avium Complex Pulmonary Disease
Role: Principal Investigator
Funding: SPERO THERAPEUTICS
Mar 2021
ACTIVE
Development of CZ-02s (AIIPS), a New Class of Antibacterial for the Treatment of Drug-Resistant Bacterial Infections, including those caused by Multidrug-Resistant Yersinia pestis, Francisella tularensis, and Burkholderia mallei
Role: Co-Investigator
Funding: ADVANCED TECHNOLOGY INTERNATIONAL
via DEFENSE THREAT REDUCTION AGENCY
Nov 2020
– Jan 2022
Evaluation of escape mutants to ADG20 against SARS-CoV-2 virus using a hollow fiber infection model system
Role: Co-Investigator
Funding: ADAGIO THERAPEUTICS
Nov 2020
– Dec 2021
Project Bioshield
Role: Principal Investigator
Funding: SPERO THERAPEUTICS
Jun 2020
– May 2023
A Mechanism Based Approach to Metallo beta-Lactamase Inhibition
Role: Principal Investigator
Funding: CASE WESTERN RESERVE UNIV
via NATL INST OF HLTH NIAID
Apr 2020
ACTIVE
Battelle Subcontract 778380 SAB Year 1
Role: Co-Investigator
Funding: BATTELLE MEMORIAL INST
via DEFENSE THREAT REDUCTION AGENCY
Dec 2019
ACTIVE
Novel Strategies for Antibiotic Combinations to Combat Gram-negative Superbugs
Role: Co-Investigator
Funding: STATE UNIV OF NEW YORK BUFFALO
via NATL INST OF HLTH NIAID
Nov 2019
– Oct 2021
Ceftazidime/Avibactam plus Aminoglycoside for Ceftazidime/Avibactam Resistant KPC-3 Klebsiella pneumonia
Role: Principal Investigator
Funding: ALLERGAN SALES
Apr 2019
– Mar 2022
SBIR: Microneedle Delivery of Zanamivir for Treatment of Influenza Infections
Role: Co-Investigator
Funding: THERAPEUTIC SYSTEMS RES LABORATORIES
via NATL INST OF HLTH NIAID
Aug 2018
ACTIVE
Combating resistant superbugs by understanding the molecular determinants of target site penetration and binding
Role: Co-Investigator
Funding: NATL INST OF HLTH NIAID
Jul 2018
– Mar 2019
Confirmatory Efficacy Study in Bp Infected Mice
Role: Co-Investigator
Funding: EMERGENT BIOSOLUTIONS
via DEFENSE THREAT REDUCTION AGENCY
Jun 2018
– May 2021
Broad spectrum antibacterials selectively targeting an un-drugged site on the ribosome
Role: Co-Investigator
Funding: CURZA
via NATL INST OF HLTH NIAID
Feb 2018
– Oct 2018
Evaluation of the improved GC-072 formulation plasma and lung ELF PK in uninfected and the Bp infected mice model
Role: Co-Investigator
Funding: EMERGENT BIOSOLUTIONS
via DEFENSE THREAT REDUCTION AGENCY
Jan 2018
– Jun 2019
CZ-02 pharmacodynamic studies, A New Class of Antibiotics Selectively Inhibiting Bacterial Protein Synthesis
Role: Co-Investigator
Funding: CURZA
via BIOMEDICAL ADVANCED RES & DEVLPMT AUTHOR
Nov 2017
– Oct 2023
Next-generation combination dosing strategies to combat resistant Acinetobacter baumannii
Role: Co-Investigator
Funding: NATL INST OF HLTH NIAID
Sep 2017
– Dec 2021
A Preclinical Mouse Model of Acinetobacter buamannii Infection For Antibacterial Development
Role: Co-Investigator
Funding: UNIV OF SOUTHERN CALIFORNIA
via US FOOD AND DRUG ADMN
Sep 2017
– Sep 2018
Pharmacokinetic analysis of nonhuman primate data for US Army
Role: Co-Investigator
Funding: US ARMY MED RES ACQUISITION
Jun 2017
– Jun 2019
Can ceftazidime-avibactam be pharmacodynamically-optimized to prevent emergence of resistance by KPC3-expressing Enterobacteriaceae?
Role: Co-Investigator
Funding: ALLERGAN SALES
Aug 2016
– Jul 2022
Optimizing combination therapy for accelerate clinical cure of tuberculosis
Role: Principal Investigator
Funding: NATL INST OF HLTH NIAID
Aug 2016
– Sep 2017
Dose-fractionation study for AKPN001 (ATCC 43816) for plazomicin and the pharmacokinetics-pharmacodynamics of amikacin
Role: Co-Investigator
Funding: ACHAOGEN
via BIOMEDICAL ADVANCED RES & DEVLPMT AUTHOR
Jul 2016
– May 2018
Pharmacokinetics-Pharmacodynamics of RG-6080, a Potent Non-Beta-Lactam Beta-Lactamase Inhibitor, In Combination with Meropenem, Piperacillin, and/or Cefepime for the Killing of Multidrug-Resistant Enterobacteriaceae and Pseudomonas aeruginosa in Neutropen
Role: Co-Project Director/Principal Investigator
Funding: F HOFFMANN LA ROCHE
Dec 2015
– May 2021
Rapid Identification of Optimal Combination Regimens for Pseudomonas aeruginosa
Role: Principal Investigator
Funding: NATL INST OF HLTH NIAID
Oct 2014
– Dec 2017
HDTRA114-CBM-06-1-0052 titled GC-072: The First Oral Antibiotic for the Treatment of Acute Melioidosis and Select Agents
Role: Principal Investigator
Funding: EMERGENT BIOSOLUTIONS
via US DEPT OF DEFENSE
May 2014
– May 2017
ITI Consulting Agreements
Role: Principal Investigator
Funding: MULTIPLE SPONSORS
Jul 2011
– Dec 2016
Contract NO. HHSN2722001000043C Targeted Clinical Trials to Reduce the Risk of Antimicrobial Resistance.
Role: Principal Investigator
Funding: NATL INST OF HLTH NIAID
Jun 2011
– May 2017
Optimization of Neoglycoside Antibiotics for Nosocomial Pathogens and SelectAgents
Role: Principal Investigator
Funding: NATL INST OF HLTH NIAID
Contact Details
Phones:
- Business:
- (407) 313-7060
Emails:
- Business:
- gdrusano@ufl.edu
Addresses:
- Business Mailing:
-
6550 SANGER RD
ORLANDO FL 32827 - Business Street:
-
6550 SANGER RD
ORLANDO FL 32827